Dietary human milk oligosaccharides reduce allergic airway inflammation by modulating SCFAs level and ILC2 activity
Immunology · 2024
DOI: 10.1111/imm.13845 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Xu Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China. Hauptthemen laut MEDLINE: Milk, Human, Lymphocytes, Asthma, Oligosaccharides. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China, Excellent Young Researchers Program of the 5th Affiliated Hospital of SYSU.
Abstract (Originalsprache)
Group 2 innate lymphoid cells (ILC2s) play a crucial role in the progression of asthma, yet the regulatory mechanisms modulating ILC2 responses in asthma remain underexplored. Human milk oligosaccharides (HMOs), vital non‐nutritive components of breast milk, are known to significantly shape immune system development and influence the incidence of allergic diseases. However, their impact on ILC2‐driven asthma is not fully understood. Our research reveals that dietary HMOs act as potent inhibitors of ILC2 responses and allergic airway inflammation. Treatment with 2′‐fucosyllactose (2'‐FL) and 6′‐sialyllactose (6'‐SL) significantly reduced ILC2‐related airway inflammation induced by papain or Alternaria alternata in mice, evidenced by decreased eosinophil (EOS) infiltration and lower IL‐5 and IL‐13 levels in BALF. Notably, while ILC2 expresses HMO receptors, HMO did not act directly on ILC2 but potentially modulated their activity through alterations in gut microbiota derived SCFAs. HMO treatments alleviated airway inflammation in SCFA‐dependent manners, with SCFA depletion or receptor blocking reversing these beneficial effects. This study reveals the potential of dietary HMOs in managing asthma through modulation of ILC2 activity and the gut‐lung axis, proposing a new therapeutic avenue that utilises the immunomodulatory capacities of nutritional components to combat respiratory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
- Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- The Affiliated Junior Secondary School of Sun Yat-sen University Zhuhai Campus, Zhuhai, China.
ORCID-Profile: Qiang Xiao
Förderung
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
- Excellent Young Researchers Program of the 5th Affiliated Hospital of SYSU
Zitieren
APA
Han, X., Wang, Z., Cao, H., Liu, W., Sun, L., & Xiao, Q. (2024). Dietary human milk oligosaccharides reduce allergic airway inflammation by modulating SCFAs level and ILC2 activity. Immunology. https://doi.org/10.1111/imm.13845
Vancouver
Han X, Wang Z, Cao H, Liu W, Sun L, Xiao Q. Dietary human milk oligosaccharides reduce allergic airway inflammation by modulating SCFAs level and ILC2 activity. Immunology. 2024. doi:10.1111/imm.13845
BibTeX
@article{Han2024,
author = {Han, Xu and Wang, Zhongjie and Cao, Hongchuan and Liu, Weiwei and Sun, Lijie and Xiao, Qiang},
title = {Dietary human milk oligosaccharides reduce allergic airway inflammation by modulating SCFAs level and ILC2 activity},
journal = {Immunology},
year = {2024},
doi = {10.1111/imm.13845}
}
EUVIMED